New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients
The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan from Mahidol University’s Siriraj Hospital in Bangkok, and was presented by X-ZELL Founder & CEO, Dr Sebastian Bhakdi.
According to Dr Bhakdi, tumours start shedding atypical cells into the blood when they are only 1-2 mm in size. Being able to detect – and understand – these cells could be key to non-invasive early cancer detection.
In previous studies focusing on prostate cancer patients, X-ZELL was able to identify individual, tumour-associated atypical cells in 10mL blood and visualise them for AI-assisted analysis.
“It’s still early days but we are confident that our single-cell diagnostics technology is able to detect atypical cells in the blood that are linked to a lung carcinomas,” he explained. “After demonstrating the same in the blood of prostate cancer patients, this could be an important step towards establishing single-cell diagnostics as a powerful new tool in the fight against cancer.”
To access the ECC 2021 abstract, titled The immunocytomorphological landscape of tumour-associated circulating atypical cells in the blood of lung cancer patients, click here to download the official abstract book or scroll down to the bottom of the page for a preview.